Treatment of rosacea The FDA approved the first local therapy for minotin

, Menlo Therapeutics announced that the U.S. FDA has approved the development of its wholly-owned subsidiary, Foamix Pharmaceuticals, to list Zilxi (1.5% minocyline, FMX103) for the treatment of adult patients with rosacea. Zilxi is the first fdable-approved local therapy for minotin in adult patients with rosacea, according to the press release.Rosacea, also known as Rosacea, is a variety of skin diseases whose most common symptoms are deep redness of the face, dilation of capillaries, and acne-like inflammatory lesions (papules and pustules). The disease can cause psychosocial burdens for patients, such as embarrassment, anxiety and low self-esteem, as well as negative effects on quality of life. Rosacea is most common in adults between the ages of 30 and 50. In the United States, more than 16 million people suffer from rosacea, and up to 28 percent of them suffer from inflammatory damage.Minotin is a broad-spectrum antibiotic with good anti-inflammatory properties. However, its application in some patients is limited due to systemic side effects caused by oral use. Zilxi is a product developed by the company using its proprietary Molecular Stability Technology (MST) platform to effectively deliver minotin locally in the form of foam.Zilxi's approval was based primarily on two clinical trial data from 1,522 patients aged 18 and older. The two studies were conducted over a 12-week multi-center, randomized, double-blind, controlled group. The joint efficacy endpoints of the two studies were absolute changes in the count and baseline of inflammatory lesions in patients in week 12 of treatment, and the proportion of patients with an IGA score of 0 (cleared) or 1 (almost cleared) in week 12. Zilxi reached the primary endpoint in both studies, showing significant improvements in inflammatory lesions counting and IGA assessment of treatment effectiveness.“ This is the only approved localized treatment with minotin," said Dr. Iain Stuart, Menlo's chief scientific officer. "(Pharmaceutical Mingkangde)